Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one‐stop clinic: a review of three years prospective experience

Objective To evaluate the performance of a one‐stop multidisciplinary clinic of screening for fetal chromosomal anomalies in the first trimester of pregnancy by a combination of maternal serum biochemistry and ultrasonography.

[1]  K. Nicolaides,et al.  Maternal age and gestational age-specific risk for chromosomal defects. , 1995, Fetal diagnosis and therapy.

[2]  J. Grudzinskas,et al.  Screening for Down syndrome in the first trimester. , 1995, Reproduction, fertility, and development.

[3]  K. Nicolaides,et al.  Maternal serum free β‐hCG and PAPP‐A in fetal sex chromosome defects in the first trimester , 2000, Prenatal diagnosis.

[4]  K. Nicolaides,et al.  A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A , 1999, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[5]  K. Nicolaides,et al.  UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation , 1998, The Lancet.

[6]  K. Nicolaides,et al.  Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. , 1992, BMJ.

[7]  S. Cicero,et al.  Screening for triploidy by fetal nuchal translucency and maternal serum free β‐hCG and PAPP‐A at 10–14 weeks of gestation , 2000, Prenatal diagnosis.

[8]  K. Spencer,et al.  First‐trimester biochemical screening for fetal chromosome abnormalities and neural tube defects , 1993, Prenatal diagnosis.

[9]  A. Mcguire,et al.  Antenatal screening for Down's syndrome. , 1992, Journal of medical screening.

[10]  K. Spencer,et al.  Free β-hCG as first-trimester marker for fetal trisomy , 1992, The Lancet.

[11]  K. Spencer,et al.  Prenatal screening for trisomy 18 with free beta human chorionic gonadotrophin as a marker. , 1993, BMJ.

[12]  K. Nicolaides,et al.  Fetal exomphalos at 11 to 14 weeks of gestation. , 1995, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[13]  J. Egan,et al.  Estimates for the sensitivity and false‐positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustment for cross‐identification and double‐positive results , 2001, Prenatal diagnosis.

[14]  A. Culyer,et al.  Effectiveness and efficiency of methods of dialysis therapy for end-stage renal disease: systematic reviews. , 1998, Health technology assessment.

[15]  K. Nicolaides,et al.  Maternal Serum Pregnancy-Associated Plasma Protein a and Fetal Nuchal Translucency Thickness for the Prediction of Fetal Trisomies in Early Pregnancy , 1994, Obstetrics and gynecology.

[16]  K. Spencer.  What is the true fetal loss rate in pregnancies affected by trisomy 21 and how does this influence whether first trimester detection rates are superior to those in the second trimester? , 2001, Prenatal diagnosis.

[17]  N. Wald,et al.  Combining Ultrasound and Biochemistry in First‐Trimester Screening for Down's syndrome , 1997, Prenatal diagnosis.

[18]  K. Nicolaides,et al.  Ultrasound screening for anencephaly at 10–14 weeks of gestation , 1997, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[19]  K. Nicolaides,et al.  One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. , 2001, BJOG : an international journal of obstetrics and gynaecology.

[20]  H. Cuckle.  Time for total shift to first-trimester screening for Down's syndrome , 2001, The Lancet.

[21]  Evaluation of effect of analytical imprecision in maternal serum screening for Down's syndrome , 2001, Annals of clinical biochemistry.

[22]  N J Wald,et al.  MATERNAL SERUM-ALPHA-FETOPROTEIN MEASUREMENT IN ANTENATAL SCREENING FOR ANENCEPHALY AND SPINA BIFIDA IN EARLY PREGNANCY Report of U.K. Collaborative Study on Alpha-fetoprotein in Relation to Neural-tube Defects , 1977, The Lancet.

[23]  K. Nicolaides,et al.  ULTRASOUND SCREENING FOR SPINA BIFIDA: CRANIAL AND CEREBELLAR SIGNS , 1986, The Lancet.

[24]  K. Spencer,et al.  Screening for trisomy 13 by fetal nuchal translucency and maternal serum free β‐hCG and PAPP‐A at 10–14 weeks of gestation , 2000, Prenatal diagnosis.

[25]  H. Cuckle,et al.  Appropriate biochemical parameters in first‐trimester screening for Down syndrome , 1999, Prenatal diagnosis.

[26]  D. Krantz,et al.  First‐Trimester Down Syndrome Screening Using Dried Blood Biochemistry and Nuchal Translucency , 2000, Obstetrics and gynecology.

[27]  B. Brambati,et al.  Ultrasound and Biochemical Assessment of First Trimester Pregnancy , 1991 .

[28]  D. Krantz,et al.  First‐trimester screening for fetal aneuploidy: biochemistry and nuchal translucency , 1997, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[29]  S. Read,et al.  Evaluation of nurse triage in a British accident and emergency department. , 1992, BMJ.

[30]  T. Chard,et al.  The Embryo : normal and abnormal development and growth , 1991 .

[31]  K. Spencer,et al.  Screening for trisomy 18 by fetal nuchal translucency and maternal serum free β ‐hCG and PAPP‐A at 10–14 weeks of gestation , 1999, Prenatal diagnosis.

[32]  K. Spencer.  Second trimester prenatal screening for Down's syndrome using alpha‐fetoprotein and free beta hCG: a seven year review , 1999, British journal of obstetrics and gynaecology.

[33]  K. Spencer.  Point-of-care screening for chromosomal anomalies in the first trimester of pregnancy. , 2002, Clinical chemistry.

[34]  K. Nicolaides,et al.  Maternal age‐ and gestation‐specific risk for trisomy 21 , 1999, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[35]  K. Nicolaides,et al.  Maternal serum alpha‐fetoprotein in fetal neural tube and abdominal wall defects at 10 to 14 weeks of gestation , 1997, British journal of obstetrics and gynaecology.

[36]  K. Nicolaides,et al.  A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free β‐hCG and PAPP‐A , 2002, Prenatal diagnosis.